Immunomedics Provides Update On Phase 2 Study Of Isactuzumab Govitecan In Patients With Diverse Metastatic Solid Cancers
October 29, 2014 at 15:03 PM EDT
Immunomedics, Inc., (Nasdaq: IMMU) today announced that isactuzumab govitecan (IMMU-132), the Company's proprietary solid-tumor ...